NovaBiotics Ltd - Townsend Investments

NovaBiotics Ltd

NovaBiotics Ltd, Biotechnology Company - Townsend Investments NovaBiotics Ltd, Biotechnology Company - Townsend Investments
Go Back

NovaBiotics Ltd is a clinical-stage speciality biotechnology company focused on the application of first-in-class anti-infective technology for difficult-to-treat, medically unmet fungal and bacterial conditions.

As a leading innovator in the anti-infectives space, NovaBiotics' business model is to develop candidate therapeutics to early/mid clinical stage prior to further development of product candidates and technology platform with commercialisation, out-licensing or co-development partners thereafter.  This model has been validated with the recent signing of a licence and co development agreement with Taro Pharmaceuticals North America Inc. for its lead product Novexatin®.

Using informed, rational drug design principles versus high-risk screening strategies, the company has developed an exciting pipeline of products utilising this streamlined process to deliver them to clinic in less than 5 years from patent priority dates.

Founded in Aberdeen by Dr. Deborah O'Neil in 2004, the Company has a wealth of expertise in the biotechnology and pharmaceutical sector and the team Deborah has built (comprising immunology, microbiology and antimicrobial peptide expertise) provides the Company with all the sector-specific skills to continue its unrivalled anti-infective business development.

Further information on NovaBiotics Ltd is available at:

View News

NovaBiotics Ltd Testimonial

“The Townsend family first invested in NovaBiotics in 2006 and has continued to support the company as a major cornerstone funder, both through further investments and by introducing other ‘High Net Worth’ individuals. This has been key in enabling NovaBiotics to successfully develop  the company’s lead compound, Novexatin®, a first-in-class antifungal peptide treatment for fungal nail infections.

Without the belief and support of our shareholders, Novexatin® and our exciting pipeline would not be where it is today”.

Dr. Deborah O’Neil, CEO & CSO, Founder – NovaBiotics Ltd

View Our Other Company Investments